cyrilzakka/clinical-trials huggingface dataset:
Telerehabilitation As Follow-up for Obesity

The goal of this experimental study is to observed the impact of telerehabilitation modalities in obese patient after a hospitalization on physical intensity at home (MVPA). The secondary aim is to observe the evolution of clinical parameters such as anthropometric data, adherence and psychological state.


Eligibility Criteria:
Inclusion Criteria:

* Adult (\> 18 years old)
* BMI \> 35 or 30 Kg/m2 in case of concomitant comorbidity
* Authorization to practice physical activity for participants over 30 years old by means of a cardiac assessment and an ECG less than 6 months old carried out by a cardiologist. As part of the COBD treatment, the ECG is either: integrated into the patient file before hospitalization if the patient has seen his cardiologist staff. Either the ECG is provided in the file or carried out and analyzed by the center's cardiologist (Dr Rouffaud). The latter then authorizes or not the practice of PA.
* Complete 3-week stay in an obesity center
* Availability of equipment suitable for telerehabilitation at home
* Having given informed consent for participation in the study

Exclusion Criteria:

* Medical contraindication to PA practice defined by a doctor
* Participation in a concomitant research protocol
* For women of childbearing age, they will be informed that in the event of pregnancy occurring during participation in the research, they will not be able to continue the protocol and will withdraw from the research
* Refusal to participate in the research protocol
* Patient on weekday stay (\< 3 weeks)
* Psychiatric/psychological disorder limiting the expression of consent
* Persons under legal protection or unable to express their consent
* Inability to participate in any of the 18 Telerehabilitation sessions
Genetic Basis of Rosacea

Rosacea is a common disease characterized by inflammation and vascular abnormalities of the facial skin and ocular surface. The exact pathogenesis of papulopustular rosacea is not well understood and current methods to treat this disease are often unsatisfactory. The purpose of this study is to develop gene expression profiles of papulopustular rosacea compared to those of normal skin. The investigators hope to better understand the abnormal gene functions that might contribute to this condition. This understanding may lead to the development of additional and better treatments for rosacea.


Eligibility Criteria:
Eligibility Criteria for Rosacea Group:

Inclusion criteria for rosacea participants:

1. Clinical signs and symptoms of rosacea (papulopustular or erythrotelangiectatic subtypes) present at enrollment as determined by the investigator
2. All four grandparents of European descent
3. Fitzpatrick skin type I or II
4. Age 18 years or older

Exclusion criteria for rosacea participants:

1. Unable or unwilling to provide written informed consent
2. Concomitant facial or medical condition that obscures diagnosis of rosacea (such as malar erythema from lupus erythematosus)
3. Acne vulgaris
4. Unable or unwilling to provide peripheral blood sample (a few teaspoons)
5. Inability for investigator to verify rosacea diagnosis on clinical examination due to rosacea treatment(s) leading to complete lack of signs and symptoms (such prior laser treatments, systemic tetracycline usage, etc.)
6. Use of topical prescription medications or procedures to the face within one month of enrollment
7. Women who are pregnant or lactating

Eligibility Criteria for Non-Rosacea Group:

Inclusion criteria for control participants:

1. No history of rosacea
2. No clinical signs or symptoms of rosacea
3. No family history of rosacea
4. All four grandparents of European descent
5. Fitzpatrick skin type I or II
6. Age 18 years or older

Exclusion criteria for control participants:

1. Unable or unwilling to provide written informed consent
2. Acne vulgaris
3. Unable or unwilling to provide peripheral blood sample (a few teaspoons)
4. Women who are pregnant or lactating
5. Use of topical prescription medications or procedures to the face within one month of enrollment
6. Skin conditions that might interfere with interpretation of procedure results (at the discretion of the investigator)
Single Incision Laparoscopic Surgery in Treating Patients With Colorectal Disease

This study is being done to evaluate single incision laparoscopic surgery (SILS) for colorectal diseases, compared to multi-port laparoscopic surgery. This study is also intended to standardize the SILS technique for colorectal diseases

PRIMARY OBJECTIVES:

I. To report the experience of SILS procedure in the treatment of colorectal disease.

II. To standardize the SILS technique.

OUTLINE:

Patients undergo single incision laparoscopic surgery with GelPort® attachment.

After completion of study treatment, patients are followed up at 2 weeks, 3 and 6 months, and at 1 year.

Eligibility Criteria:
Inclusion Criteria:

* Patients who are willing to give consent and comply with the evaluation and the treatment schedule
* Patients with disease processes limited to the right colon; this will include Crohn's disease, polyp disease, and cancers of the right colon
* American Society of Anesthesiologists (ASA) =\< 3

Exclusion Criteria:

* Inability to obtain informed consent
* Previous right colon surgery
* Previous extensive abdominal surgery that would limit the laparoscopic approach
* Stage IV disease at surgery
* Metastatic disease diagnosed by computed tomography (CT), magnetic resonance imaging (MRI), or nuclear imaging
* Patient enrolled in other interventional study
* ASA score greater than 3
* Any condition which precludes compliance with the study (Investigator discretion)
* Co-morbid condition(s) that could limit the subject's ability to participate in the study or to comply with follow-up requirements, or that could impact the scientific integrity of the trial
Gingival Wetness and Gingival Crevicular Fluid Volume in Patients With Dry Mouth

The investigators questioned whether patients with dry mouth complaints display any reduction in residual saliva coating the gingiva and other selected mucosal surfaces. We further intended to test the hypothesis that Gingival Crevicular Fluid volume in patients with dry mouth could be different from that of control subjects. Correlations between gingival/mucosal wetness; and unstimulated whole salivary flow rate or minor salivary gland secretion rates and the correlations between clinical periodontal status and salivary measures were also attempted.


Eligibility Criteria:
Inclusion Criteria:

* For test group dry mouth complaints and with a diagnosis ofSjogren's Syndrome

Exclusion Criteria:

* Other medical problems that effect salivary glands
Venous Pressure Measurement of the Great Saphenous Vein Using Controlled Compression Ultrasound in Healthy Persons and Patients With Chronic Venous Disease as a New Non Invasive Method for Investigation of the Pathophysiology in Primary Varicose Veins

Part I:

Proof of concept trial to achieve normal venous pressure values under different provocation maneuvers in healthy persons

Part II:

Non invasive measurement of venous pressure under different provocation maneuvers in patients with chronic venous disease


Eligibility Criteria:
Inclusion criteria:

Part I:

* Healthy persons without clinical signs of venous disease, informed consent

Part II:

* Patients with chronic venous disease with complete incompetence of the great saphenous vein (Hach IV)
* Informed consent

Exclusion criteria:

Part I:

* Clinical signs of venous disease, former deep vein thrombosis (DVT)

Part II:

* Former deep vein thrombosis, former vein surgery
Impact of Five Love Languages on Cancer Patients

The objective of this study is to evaluate the effectiveness of an intervention utilizing the Five Love Languages on quality of life (pain, depression, and anxiety) of cancer patients.


Eligibility Criteria:
Inclusion Criteria:

* Patients diagnosed with cancer with a significant other who attend a Texas Oncology couples support group will serve as the study population

Exclusion Criteria:

* N/A
A Pharmacokinetic Study to Evaluate the Drug Interaction Between HRS5091 and Probe Drugs in Healthy Volunteers

This is a drug-drug interaction study conducted in healthy volunteers to evaluate the effect of HRS5091 on CYP3A4, CYP2C9, CYP2C19, P-gp, BCRP and OATP1B1, using midazolam, s-warfarin, omeprazole, digoxin and rosuvastatin as probe drugs.


Eligibility Criteria:
Inclusion Criteria:

1. The subject can communicate well with the researcher, understand and comply with the requirements of this study, and understand and sign the informed consent;
2. Healthy subjects aged 18\~50 (including 18 and 50 years old);
3. Body weight ≥ 50 kg, body mass index (BMI) within the range of 19 \~ 26 kg /m2 (including 19 and 26 kg/m2) (BMI= weight (kg)/height2 (m2));
4. Give informed consent not to have a family plan for six months after the last dose, and agree to take effective contraception.

Exclusion Criteria:

1. Has the medicine or food allergy history, or is the allergic constitution person;
2. Inability to swallow, chronic diarrhea and intestinal obstruction, or the presence of a variety of other factors affecting drug use and absorption;
3. QTCF \> 450 ms in 12-lead ECG examination or other abnormal conditions judged by the researchers to have clinical significance;
4. Hepatitis B surface Antigen (HBSAG), Hepatitis C virus antibody, human immunodeficiency virus (HIV) antibody, syphilis antibody test positive;
5. Those who smoked more than 5 cigarettes per day within 3 months before screening and could not stop using any tobacco products during the trial period;
6. Regular drinkers who had consumed more than 14 units of alcohol per week (1 unit = 285 ml of beer, 25 ml of spirits, or 100 ml of wine) during the six months prior to screening and could not stop using any alcoholic product during the trial; positive Breath test for alcohol;
7. Having a history of drug abuse, drug dependence (consultation) or positive urine drug abuse screening before drug administration;
8. Anyone who has undergone any surgery within 6 months prior to screening;
9. Clinical trial participants who have participated in any drug or medical device within 3 months prior to screening (subject to the intervention of the experimental drug or medical device);10.Blood donation (or blood loss) within 3 months before screening and the amount of blood donation (or blood loss)≥400 ml, or receiving blood transfusion.
Comparison of His Bundle Pacing and Bi-Ventricular Pacing in Heart Failure With Atrial Fibrillation

This study is a multicenter, prospective, randomized cross-over study to compare His Bundle Pacing (HBP) with Bi-Ventricular Pacing (BiVP) in HF Patients with AF who need atrial-ventricular node ablation.

Patients who meet the inclusion and exclusion criteria will be enrolled into the study. In the study, both atrial-ventricular node(AVN) ablation and Cardiac Resynchronization Therapy (CRT) implantation are performed with HBP lead implanted and connected with the A port of CRT device. Followed with successful AVN ablation, HBP lead and CRT implantation, patients are 1:1 randomized into BiVP and HBP group for 9 months and then crossover for another 9 months. The primary end points of the study is the change of left ventricular ejection fraction (LVEF) in both HBP and BiV pacing group.

Eligibility Criteria:
Inclusion Criteria:

* Subject is at least 18 years old
* Subject or authorized legal guardian or representative has signed and dated the Informed
* Subject is expected to remain available for follow-up visits at the study center
* Subjects with heart failure NYHA Class II-IV
* Subjects with LVEF no greater than 40%
* Subjects with persistent atrial fibrillation or atrial flutter with uncontrolled ventricular rate

Exclusion Criteria:

* Subjects with the width of ECG Q, R, S wave (QRS) complex \>120ms
* Subjects with life expectancy less than 3 years
* Subjects with mechanical right heart valve
* Subjects with primary valvular disease
* Subjects with heart transplant, or is currently on a heart transplant list
* Subjects who are pregnant, or of childbearing potential and not on a reliable form of birth control
* Subjects with significant renal dysfunction, as manifested by serum creatinine level \>2.5 mg/dl or ≥275 μmol/L or estimated glomerular filtration rate (GFR) ≤30 mL/min/1.72 m2, which is documented within the 30 days prior to enrollment or at baseline.
* Subjects with significant hepatic dysfunction, as evidenced by a hepatic function panel (serum) \> 3 times upper limit of normal, which is documented within the 30 days prior to enrollment or at baseline.
* Subjects with chronic or treatment-resistant severe anemia (hemoglobin \<10.0 g/dL), which is documented within the 30 days prior to enrollment or at baseline
Early Detection and Treatment of Esophageal Injury After Catheter Ablation for Atrial Fibrillation

The purpose of this study is to prospectively follow the next 200 patients who undergo catheter ablation of atrial fibrillation for symptoms and signs of esophageal injury.

The purpose of this study is to prospectively follow the next 200 patients who undergo catheter ablation of atrial fibrillation and endoscopy. If any signs of esophageal injury are seen on endoscopy the patients will be treated with omeprazole and sucralfate and they will have repeat endoscopy in two weeks. Patients who do not have any esophageal injury will be contacted by telephone in two weeks to be assessed for GI symptoms.

Specific Aims: The specific aims of the study are to:

1. Assess the incidence of visible transmural esophageal injury following extensive ablation in the posterior left atrium as measured by endoscopy1
2. Assess whether early detection of esophageal injury by endoscopy and treatment will prevent development of more serious injury such as left atrial-esophageal fistula
3. Identify predictors of esophageal injury. In particular, to assess if esophageal temperature rises during ablation correlate with development of esophageal injury and if the absence of esophageal temperature rise during ablation correlate with the absence of esophageal injury.

Eligibility Criteria:
Inclusion Criteria:

* 18-80 years
* Scheduled to have catheter ablation of atrial fibrillation or left atrial macroreentrant tachycardia.

Exclusion Criteria:

* Contraindication to endoscopy
* Pregnancy
* Prisoners
* Inability or unwillingness to give informed consent
ArtiSential® for Rectal Cancer Surgery

This study aimed to assess efficacy of ArtiSential® in reducing laparoscopic rectal cancer surgery duration. We retrospectively reviewed the data of patients who underwent laparoscopic low or ultralow anterior resection for primary mid-to-low rectal cancer, performed by a single surgeon in 2012-2022. Patients were divided into groups, use group vs. non-use group, based on the use or non-use of the ArtiSential®. The total mesorectal excision quality and resection margin status did not differ between the groups. ArtiSential® reduced operative time without impairing surgical quality or oncologic outcomes.


Eligibility Criteria:
Inclusion Criteria:

* mid-to-low rectal caner (witing 10cm of the anal verge)
* laparoscopic surgery

Exclusion Criteria:

* combined surgery
* recurrent rectal cancer surgery
An Observational Study to Identify New Health Problems Arising After an Intensive Care Unit Admission in People With Acute Respiratory Distress Syndrome in the United States

This is an observational study in which data already collected from people with acute respiratory distress syndrome (ARDS) admitted to an intensive care unit (ICU) are studied.

ARDS is a life-threatening condition in which fluid builds up in the lungs making breathing difficult.

In observational studies, only observations are made without participants receiving any advice or any changes to health care.

People who are admitted to ICU for serious illnesses, like ARDS, often experience new health problems during and after their ICU stays. These health problems that may include physical, mental, and/or emotional disorders, are called post-intensive care syndrome (PICS). Identifying these new health problems early can help people by timely treatments and care.

In this study, researchers want to identify any health problems that arise after ICU admission in people with ARDS in the United States (US). To do this, researchers will collect information on health problems, treatments, medicines, and healthcare visits in people with ARDS, 1 year before and after an ICU admission.

They will then look to see whether the health problems are in areas that have been described as the post intensive care syndrome (PICS).

In addition, they will measure healthcare related costs in the one year after admission and compare it to the one year prior to admission.

Researchers will also compare this information with data collected for people with pneumonia who did not require ICU admission. This will help them to identify any new health problems arising due to ICU stays.

The data will come from participants' medical claims information stored in the Optum Clinformatics Data Mart database from 2016 to 2022. The claims data will only be collected for people in the US.

Researchers will collect data from participants admitted to ICU for ARDS for a maximum of 1 year before and after their stay.


Eligibility Criteria:
Inclusion Criteria:

* continuous coverage of at least 365 days (\>= 1 year) pre-index date for the cohort
* age \>= 18 years
* not seen outside the healthcare system

Exclusion Criteria:

* none
Whether it is More Appropriate to Spray Lugol's Solution From Cervical Esophagus to Esophagogastric Junction

The aim of this study is to compare the effectiveness and safety of spraying Lugol's solution from cervical esophagus to esophagogastric junction (downward) and from esophagogastric junction to cervical esophagus （upward）during chromoendoscopy.

Chromoendoscopy using Lugol's solution is effective for the detection of early esophageal squamous neoplasia. However, there is no study to investigate the sequence of Lugol's staining during endoscopic procedure.

The aim of this study is to compare the effectiveness and safety of spraying Lugol's solution from cervical esophagus to esophagogastric junction (downward) and from esophagogastric junction to cervical esophagus （upward）during chromoendoscopy.

Eligibility Criteria:
Inclusion Criteria:

* High risk patients of early esophageal squamous neoplasias.

Exclusion Criteria:

* After esophageal surgery or endoscopic treatment ;
* Known esophageal radiotherapy or chemotherapy ;
* Esophageal stenosis;
* Acute bleeding;
* A known allergy to iodine;
* Coagulopathy (prothrombin time \<50% of control, partial thromboplastin time \>50 seconds);
* Having food retention;
* Severe hepatic ,renal, cardiovascular or metabolic dysfunction ;
* Being pregnant or lactating.
Trial Evaluating Postop Pain and Muscle Strength Among Regional Anesthesia Techniques for Ambulatory ACL Reconstruction

Despite the apparent multifaceted benefit in differentiating blockade sites and duration of nerve blockade, the efficacy of continuous adductor canal blockade utilized specifically in ACL reconstruction has not been extensively studied. This study will test the hypothesis that the use of the adductor canal continuous nerve catheter will result in lower subjective pain scores on postoperative day 2 and improved quadriceps strength on postoperative day 1.

Study participants will be randomized to 2 groups: (1) continuous adductor canal nerve catheter or (2) long-acting single bolus adductor canal nerve block.

Following random selection via random envelope selection patients will receive the following procedures. Both groups will receive ultrasound guided femoral nerve block with 20cc of 2% mepivacaine \<20 minutes prior to in room time.

Intraoperative care will consist of general anesthesia under the care of the attending anesthesiologist assigned to the patient. Induction will include a propofol bolus and placement of laryngeal mask airway. Intraoperative opioid should be limited to no more than 150mcg of fentanyl. Upon completion of wound closure, appropriate dressing placement, emergence from anesthesia and removal of LMA, patients to be taken to PACU. Once adequately awake and alert, Group 1 patients 1 will receive ultrasound guided adductor canal continuous nerve catheter using normal saline as bolus for placement, followed by initiation of 1/8% bupivacaine infusion through catheter at 8cc/h. Group 2 will receive ultrasound guided adductor canal nerve block with 10cc of 0.5% ropivacaine + 2mg dexamethasone (0. 5cc), keeping total injectate at 10.5cc to spare significant proximal spread to femoral nerve14. After adequate instruction including catheter education (if applicable) patients are to be discharged home.

Eligibility Criteria:
Inclusion Criteria:

* Age 14 and older
* Patients who are scheduled to undergo an ACL reconstruction with patella or allograft
* Patient does not have a contraindication to receiving regional anesthesia

Exclusion Criteria:

* Allergy to local anesthetics, dexamethasone, or adhesive tape
* Patients undergoing hamstring graft for ACL
* Preexisting infection at site of needle insertion
* Immunocompromised patients
* Preexisting sensory or motor deficit in operative extremity
* Patient on chronic opioid treatment.
* Patient having a revision of previous ACL reconstruction.
* Pregnancy and lactating women
Patterns of Care and Outcomes of Patients With METAstatic Gastrointestinal Stromal Tumors (METAGIST)

Gastro intestinal stromal tumors (GIST) are rare mesenchymal tumors of the gastrointestinal tract characterized by somatic mutations in the gene encoding the KIT or the PDGFR alpha protein1. Treatment of localized forms relies on adequate surgery without tumor spillage and systemic treatment with imatinib according to risk of relapse defined by localization, tumor size and mitotic count, as well as mutational status. Advanced and relapsing forms are currently treated with oral tyrosine-kinase inhibitors (TKI) of KIT and PDGFR such as Imatinib, Sunitinib and Regorafenib. Over two decades significant changes in drug discovery have impacted treatment strategies, notably via patient's access to various clinical trials. The use of focal treatments such as surgery or interventional radiology with mini invasive procedure of oligometastasis is also being proposed in some cases.

There is no precise data on patterns of sequential treatments used, especially proportions of patients with metastatic GIST eventually benefiting from access to a clinical trial or a focal treatment strategy in the course of their disease, and their results in terms of survival on a real life national level.

Using the French sarcoma Group national database we aim at describing treatments strategies proposed patients with metastatic GIST in the real life setting.

Objectives include : (i) Description of clinico-biological profiles, patterns of care and modalities of treatment of patients with metastatic GIST in a real-life national setting and (ii) evaluation of impact of each treatment line on patients outcome in terms of time to next treatment (TNT) and survival


Eligibility Criteria:
Inclusion Criteria:

* patients ≥ 18 years old
* with a diagnosis of metastatic Gastrointestinal Stromal Tumor (metastatic at diagnostic or metastatic relapse)
* From 1990 to 2018

Exclusion Criteria:

-